Lincoln Tech Celebrates 500th Graduate of Johnson Controls Academy

Program builds skilled talent pipeline to support increasingly complex, energy intensive environments

Parsippany, NJ, Aug. 20, 2026 (GLOBE NEWSWIRE) — Lincoln Educational Services Corporation (NASDAQ: LINC), a national leader in specialized automotive and skilled trades career training, today announced the most recent class of graduates from the Johnson Controls (JCI) Academy included the program’s 500th graduate. This marks a significant milestone in developing the skilled workforce needed to support mission‑critical environments across the United States. Johnson Controls established the JCI Academy at Lincoln Tech’s Columbia, Maryland campus in 2022 to focus on training security and fire alarm installation and service technicians. A second location opened at Lincoln’s Denver campus in 2024.

The Academy builds on a broader partnership between Johnson Controls and Lincoln Tech that began in 2018 to train electricians, electronic service technicians and HVAC-R technicians at Lincoln Tech schools nationwide. Students who complete the program transition directly into full-time roles with Johnson Controls. To date, more than 500 participants have been trained across the HVAC-R, Data Center, Fire, and Security career fields.

“When we first partnered with Johnson Controls eight years ago, we were fully committed to assisting them in building their workforce any way we could,” says Scott Shaw, Lincoln Tech’s President and CEO. “Launching the JCI Academy was a major part of that commitment, helping to set students on
pathways to careers that align with market needs. Knowing that we’ve now surpassed 500 graduates from the highly specialized Johnson Controls Academy program is a proud moment for our campuses and for all of the people working to making this partnership as successful as it has been.”

“Demand for skilled talent continues to grow alongside the increasing complexity of the environments our customers operate,” said Alison Neuman, Program Manager, Workforce Development, Johnson Controls. “Through our partnership with Lincoln Tech, we’re building the skilled workforce that will deliver the mission-critical environments and thermal management solutions powering society’s most important industries.”

“This program is crucial to help aspiring future technicians or inspectors develop their skillset,” says Donnell Talley, who graduated from the JCI Academy at Columbia in March. Talley now works for Johnson Controls as a Fire Service Technician in New York.  “I can’t recommend or sing the praises of the Academy enough.”

The JCI Academy is a six-week advanced training program that focuses on security installation and fire services systems, providing a pathway to employment at JCI locations throughout the United States. JCI covers tuition, housing and relocation expenses for students in an effort to continue bridging the skills gap in the building technology field. A third JCI Academy site is slated to open later this year at Lincoln Tech’s Indianapolis campus.

###

About Lincoln Educational Services Corporation 

Lincoln Educational Services Corporation is a leading provider of diversified career-oriented post-secondary education. Lincoln offers recent high school graduates and working adults career-oriented programs in four principal areas of study: transportation, healthcare, skilled trades, and information technology. Lincoln has provided the workforce with skilled technicians since its inception in 1946.

Lincoln currently operates 22 campuses in 12 states under 3 brands: Lincoln College of Technology, Lincoln Technical Institute, and Nashville Auto-Diesel College.

For more information, go to lincolntech.edu.



Scott Watkins, VP Marketing
Lincoln Tech
973.766.9656 
[email protected]

Halliburton Labs Announces Three New Portfolio Companies

Halliburton Labs Announces Three New Portfolio Companies

Electroflow, Osmoses, and SiTration Join Halliburton Labs to Accelerate Commercialization and Industrial Scale-Up

HOUSTON–(BUSINESS WIRE)–
Halliburton Labs today announced the addition of three companies to its collaborative ecosystem: Electroflow, Osmoses, and SiTration. The selected ventures develop breakthrough technologies that address critical challenges in battery materials, resource recovery, and gas separations. These companies confront the material and process bottlenecks that stand between today’s energy system and tomorrow’s opportunities.

Halliburton Labs collaborates with early-stage hard-tech ventures to scale innovative technologies through industry expertise, world-class facilities, and a global network of industrial and investment partners.

“Affordable and reliable molecules are essential building blocks of the energy future,” said Andres Cabada, Halliburton Labs managing director. “Each company brings a bold, technical solution to a complex industrial challenge. We look forward to helping them scale and deploy their technologies.”

Electroflow

Electroflow helps secure domestic battery supply chains through the production of lithium iron phosphate (LFP) cathode material directly from lithium brines. LFP is a critical component for affordable, safe, and long-lasting batteries used in electric vehicles, grid storage systems, and industrial electrification.

The company’s proprietary platform combines lithium extraction and cathode material production into a three-step process that can unlock low-concentration brine resources, support scalable domestic manufacturing, and strengthen North America’s battery supply chain.

Osmoses

Osmoses improves industrial gas separation, a critical process for fuels, chemicals, and other industrial products that consumes a significant portion of global energy.

Its membrane platform reduces the energy use, cost, and emissions associated gas separations for renewable natural gas, hydrogen, helium, and other industrial applications.

SiTration

SiTration unlocks a faster and lower-cost copper supply through the recovery of critical metals directly from mining waste streams. The company’s patented electro-extraction and filtration technologies support the recovery of market-grade copper in a single-step process powered solely by electricity.

With an estimated $500 billion of copper contained in mining waste globally, SiTration offers a faster, lower-cost pathway to resource recovery than new mine development. The company’s platform can also be used to recover precious metals and produce rare earth concentrates from diverse mining streams and has demonstrated success in pilot projects with Tier 1 mining companies on multiple continents.

Industrial Innovation at Scale

The addition of Electroflow, Osmoses, and SiTration reflects Halliburton Labs’ efforts to support entrepreneurs who develop practical solutions for the evolving energy and industrial landscape. Halliburton Labs provides the expertise, infrastructure, and relationships innovators require to scale and bring to market the technologies that will define the future of energy and industry.

About Halliburton Labs

Halliburton Labs provides global industrial capabilities to early-stage hard-tech energy ventures so they scale faster. Through expertise, facilities, business networks, and tailored support for the long term, Halliburton Labs helps entrepreneurs accelerate the development and deployment of solutions that address global energy and industrial challenges. Visit the company’s website at www.halliburtonlabs.com.

Connect with Halliburton Labs on LinkedIn. Halliburton Labs is a wholly owned subsidiary of Halliburton Company (NYSE: HAL).

For Investors:

David Coleman

[email protected]

281-871-2688

For Media Relations:

Alexandra Franceschi

[email protected]

281-871-3602

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Technology Other Energy Other Technology Oil/Gas Energy Other Natural Resources Batteries Mining/Minerals Natural Resources

MEDIA:

Quanome Technologies Establishes Global Quantum Council and Scientific Advisory Network

International expert platforms bring together scientific expertise across four quantum streams to advance understanding, collaboration and real-world application

ITASCA, Ill., Aug. 20, 2026 (GLOBE NEWSWIRE) —  Quanome Technologies, Inc. (Nasdaq: QNME), today announced the establishment of its Global Quantum Council and Scientific Advisory Network, bringing together recognised scientific and technical experts to strengthen the Company’s understanding of quantum science, advanced technologies and their potential applications across industry and society.

The initiative forms part of Quanome’s broader strategic vision to connect scientific expertise, technological development, industry and investment, with a focus on identifying developments that have the potential to deliver meaningful economic and societal impact. The Global Quantum Council is being established around four specialist streams:

  1. Quantum Systems – Advancing the science of quantum information, computing and communication systems.
  2. Molecular Discovery – Harnessing quantum science to accelerate the evolution of medicines that enhance access, accuracy and success of treatments for diseases and cancers
  3. Advanced Nuclear 
    Technologies – Applying quantum science to increase safety, efficiency and output of nuclear energy production, materials and adoption globally.
  4. Quantum-Safe Cybersecurity – Building the next generation of security for a quantum-enabled world.

Each stream is intended to draw on scientific and technical expertise relevant to its respective field. Together, the Council will provide an independent forum for scientific perspective, thought leadership and discussion around how quantum science can address real-world challenges and contribute to longer-term societal and economic progress.

Alongside the Council, Quanome’s Scientific Advisory Network will provide access to a broader group of specialist experts across quantum and related complex sciences, enabling the Company to engage specialist experts as opportunities arise, support scientific evaluation, explore collaborative initiatives and deepen its understanding of emerging technologies.

Yang Li, Chief Executive Officer of Quanome Technologies said,Quanome recognises the importance of bringing scientific expertise and commercial thinking together when considering the potential of quantum and complex sciences. We have already identified several subject matter experts within these four target areas of knowledge.  We are excited to finalise several of these relationships and formalize their involvement in the near term.  This is expected to be a critical aspect of our go-forward strategy in 2026 and beyond.

The two platforms are complementary. Their purpose is to broaden understanding of what is being achieved through quantum and complex science, highlight developments with practical potential, and encourage greater collaboration around initiatives that could make a tangible difference to industries, economies and societies.

Quanome intends to use the expertise and perspectives generated through these forums to help identify credible technologies, research initiatives, projects and applications that may warrant further scientific assessment, collaboration, strategic partnership or potential investment.

The Global Quantum Council and Scientific Advisory Network will operate as independent advisory forums, with participating experts contributing their own professional perspectives and expertise.


There is no single solution to the complex challenges facing industries and economies. Our objective is to engage and listen to those working at the forefront of these fields, understand where meaningful progress is being made, and help create greater awareness of the opportunities that may arise from it,
” added Li

The establishment of the two platforms represents an early step in Quanome’s strategy to develop stronger international scientific relationships and identify opportunities for future collaboration where advances in quantum science and related technologies may translate into practical, sustainable and commercially relevant outcomes.

Ends


Media / Investor Contact:


Media / Investor Relations – Lauren Callie

www.quanometech.com 
[email protected]


Editors Notes:


About Quanome Technologies, Inc.

Quanome Technologies, Inc. (Nasdaq: QNME), formerly Lakeside Holding Limited, is a U.S.-based company headquartered in Itasca, Illinois. Quanome is focused on quantum technologies, artificial intelligence and advanced computing, with a long-term focus on applications that can support innovation and improve productivity across industries.

The Company is exploring opportunities across healthcare, pharmaceutical discovery, advanced materials, energy, cybersecurity, financial services and industrial technologies, with the aim of translating advances in quantum science and related technologies into practical, real-world applications.


Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995.

Forward-looking statements include, without limitation, statements regarding the Company’s strategic transformation, development plans, technology initiatives, intended areas of focus, potential industry applications, future partnerships, software and platform development, the anticipated development and adoption of quantum technologies and post-quantum cryptography, and the Company’s strategy, objectives, opportunities, and future operations.

These statements are based on the Company’s current expectations and are subject to known and unknown risks, uncertainties, assumptions, and other factors that may cause actual results to differ materially, including the Company’s ability to develop and commercialize new technologies, establish strategic and commercial relationships, recruit and retain qualified personnel, obtain additional capital, respond to technological and competitive developments, and regain and maintain compliance with Nasdaq continued listing requirements.

Additional risks and uncertainties are described in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and subsequent reports on Forms 10-Q and 8-K.

Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update any forward-looking statement except as required by applicable law.



Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment

New Location Expected to More Than Double Annual Revenue Production Capacity to Over $10 Million

Official Grand Opening Slated for August 27 in Henderson, Nevada With Prominent Industry Opinion Leaders, Sleep Physicians, Dentists Among Scheduled Attendees

LITTLETON, Colo., Aug. 20, 2026 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (Nasdaq: VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from obstructive sleep apnea (“OSA”) and other sleep disorders, today announced the official Grand Opening of its latest state-of-the-art diagnostic, testing, and treatment location in Henderson, Nevada. The Company expects this new full-service center will more than double the annual production capacity in Henderson to more than $10 million. At full capacity, the facility is expected to employ up to 30 personnel, including board certified medical doctors, specially trained dentists, nurse practitioners, and a full complement of clinical and support personnel as part of the Company’s Sleep Centers of Nevada network.

Sleep Centers of Nevada Founder and Chief Medical Officer, R. D. Prabhu, M.D. said, “Our new Henderson facility is a state‑of‑the‑art center that brings together two highly specialized teams to deliver the most comprehensive sleep‑medicine care in Nevada. For the first time, patients can receive diagnostic testing, clinical evaluation, and advanced treatment — including FDA‑cleared oral appliance therapy, airway‑focused dental sleep medicine, laser therapy, and myofunctional therapy — all in one location.”

He continued, “We believe there is no other integrated sleep and airway center like this in the United States. With more than 200,000 Nevadans living with undiagnosed sleep apnea, this facility will make a meaningful difference in the health of our community.”

Vivos’ Chief Executive Officer, Kirk Huntsman, added, “This added production capacity will go a long way to help us keep up with the growing level of referrals coming into our centers each month. Just since the May-June timeframe, we’ve seen total incoming referrals more than double across the Las Vegas market, so this added production capacity comes at a very good time, and should have an immediate impact on revenue in that market. This new center in Henderson represents our most refined platform model where we are able to provide patients with extensive testing services as well as a full spectrum of treatment options to ensure that patients who accept treatment receive a customized plan to get started almost immediately.”

About Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc. (Nasdaq: VVOS) is a medical technology and healthcare services company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. Vivos’ devices have been cleared by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17. Vivos’ groundbreaking Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the flagship DNA appliance is the first to receive clearance for treating moderate to severe OSA in children. 

OSA and insomnia affect an estimated 1 Billion adults aged 30-69 years old worldwide, yet 80% or more remain undiagnosed and unaware of their condition. These chronic disorders are not just a sleep issue—they are closely linked to many serious chronic health conditions. While the medical community has made strides in treating sleep disorders, breathing and sleep health remain areas that are still not fully understood. As a result, legacy OSA treatments like CPAP are often mechanistic and fail to address the root causes. Vivos CARE oral medical devices are designed to help address anatomical factors are often associated with OSA.

Through innovative technology, education, and acquisitions of, or commercial collaborations with, sleep healthcare providers, Vivos is empowering healthcare providers to address the complex needs of OSA patients more thoroughly.

Vivos calls the use of its appliances and protocols to treat OSA The Vivos Method, which offers a proprietary, clinically effective solution that is nonsurgical, noninvasive, and nonpharmaceutical, providing hope to allow patients to Breathe New Life.

For more information, visit www.vivos.com.

Cautionary Note Regarding Forward‑Looking Statements

This press release, including statements of the Company’s management and other parties made in connection therewith, contains “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as “may,” “would,” “should,” “expects,” “projects,” “potential,” “intends,” “plans,” “believes,” “anticipates,” “hopes,” “estimates,” “goal,” “aim,” and variations of such words and similar expressions are intended to identify forward-looking statements. In this press release, forward-looking statements include, without limitation, statements regarding: the expected timing and benefits of the grand opening of the Company’s new Henderson, Nevada facility; the expectation that the new facility will more than double annual production capacity to more than $10 million; anticipated staffing levels at the new facility; recent patient referral trends and their anticipated impact on the Company’s revenue in the Las Vegas market; and the potential impact of the foregoing on the Company’s competitive position, revenues, and overall growth.

These statements involve significant known and unknown risks and are based upon a number of assumptions and estimates that are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results may differ materially and adversely from those expressed or implied by such forward-looking statements as a result of various factors, including, but not limited to: (i) the risk that the new facility will not be able to provide the anticipated financial and other benefits; (ii) the risk that the anticipated production capacity increases will not materialize as anticipated; (iii) the risk that new or competing technology may limit or extinguish the new location’s economic value to the Company; (iv) risks associated with regulatory scrutiny of, and adverse publicity in, the sleep apnea and sleep disorder diagnosis and treatment sector; (v) the risk that Vivos may be unable to secure additional financing to continue operations, acquire or affiliate with additional sleep center practices, or maintain its Nasdaq listing, when needed, if at all; (vi) market and other conditions that could impact Vivos’ business or ability to obtain financing; (vii) the risk that recent increases in patient referrals may not continue or may not translate into increased revenue, or that the Company may be unable to recruit and retain the qualified medical, dental and clinical personnel needed to staff and operate the new facility; and (viii) other risk factors described in Vivos’ filings with the Securities and Exchange Commission (the “SEC”), which are available free of charge on the SEC’s website at www.sec.gov.

Except to the extent required by law, Vivos expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change in events, conditions, or circumstances on which any such statement is based.

Vivos Investor Relations Contact:

Jennifer Hauser, Executive Assistant to the CEO
[email protected]
720-927-3125



GLOB Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Globant (GLOB)

GLOB Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Globant (GLOB)

Globant’s Q2 2026 report showed revenue of roughly $614.4 million — essentially flat year over year — and full-year 2026 guidance was cut from slight growth to a slight decline, sending shares sharply lower and drawing analyst downgrades. Levi & Korsinsky is investigating potential securities law violations.

NEW YORK–(BUSINESS WIRE)–
Shareholders of Globant (NYSE: GLOB) absorbed a sharp decline in the shares after the Company’s Q2 2026 earnings release, which reported revenue of approximately $614.4 million and a reduced full-year 2026 revenue forecast. Investors who lost money on GLOB are encouraged to request a review of your GLOB losses now. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

The reported quarter came in below street consensus, and the guidance revision moved the full-year outlook from expected slight growth to a slight year-over-year decline. On February 26, 2026, Globant had guided FY2026 revenue of $2,460 million to $2,510 million, implying 0.2% to 2.2% year-over-year growth. On May 14, 2026, the Company raised the low end of that range and reaffirmed the midpoint at $2,462 million to $2,508 million. The reduction followed roughly three months later.

Analysts followed with downgrades and price-target cuts citing weaker near-term growth and pressure on the legacy time-and-materials business.

If you purchased Globant shares and suffered a loss, click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

ABOUT THE FIRM — For over two decades, Levi & Korsinsky has represented shareholders in securities class actions. Ranked in ISS Top 50 for seven consecutive years.

Frequently Asked Questions About the GLOB Investigation

Q: Who is eligible to participate in the GLOB investigation? A: Investors who purchased GLOB stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses — not on whether you still hold the shares.

Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Globant made materially false or misleading statements regarding its full-year 2026 revenue outlook and near-term demand trends. When the Company reported approximately flat Q2 2026 revenue and reduced its full-year 2026 forecast to a slight year-over-year decline, the stock price declined sharply.

Q: When did Globant allegedly mislead investors? A: The investigation concerns statements made before the corrective disclosure that allegedly caused investors to purchase securities at inflated prices.

Q: What do GLOB investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my GLOB shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought GLOB and sold at a loss may still participate in the investigation.

Q: What if my GLOB losses are small — is it still worth contacting a lawyer? A: Yes. There is no minimum loss amount required to participate in the investigation.

Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys’ fees and expenses subject to court approval.

Attorney Advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

[email protected]

Tel: (212) 363-7500

Fax: (212) 363-7171

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo

MVST Deadline Alert: Levi & Korsinsky Reminds Microvast Holdings, Inc. (MVST) Investors of Securities Class Action Deadline on September 21, 2026

MVST Deadline Alert: Levi & Korsinsky Reminds Microvast Holdings, Inc. (MVST) Investors of Securities Class Action Deadline on September 21, 2026

Market-impact alert: The lawsuit alleges Microvast’s margin and capacity statements kept MVST shares inflated before a series of disclosures culminated in a 34.2% decline. This release focuses on how investors allegedly absorbed losses as the market reacted to each corrective event.

NEW YORK–(BUSINESS WIRE)–Levi & Korsinsky, LLP notifies investors in Microvast Holdings, Inc. (NASDAQ: MVST) that a class action has been filed on behalf of shareholders who purchased securities between April 1, 2025 and March 16, 2026. Find out if you may qualify to recover losses. You may also contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.

MVST fell $0.79 per share, or 34.2%, to close at $1.52 on March 17, 2026, after Microvast reported Q4 2025 revenue of $96.5 million, gross margin of 1.0%, and a $32.5 million inventory impairment. The lead plaintiff deadline is September 21, 2026.

Alleged Market Impact From Successive Disclosures

The securities action alleges that Microvast overstated its ability to reach elevated gross margin targets and complete the Huzhou Phase 3.2 expansion by the end of 2025. The filing states that investors were later confronted with disclosures concerning questioned business capabilities, finance leadership turnover, delayed production timing, customer rollout delays, and specialized ESS inventory that did not generate associated 2025 revenue.

MVST Market Reaction Sequence

  • On June 25, 2025, a short-seller report questioned Microvast’s business capabilities, Huzhou facility activity, and partnership economics, and MVST declined as much as $0.40 intraday, or approximately 10.23%.
  • On August 1, 2025, Microvast announced the departure of its CFO after roughly three months in the role, and MVST later fell $0.30 per share, or approximately 9.93%.
  • On November 10, 2025, Microvast disclosed that initial Huzhou Phase 3.2 production would follow in Q1 2026, and MVST declined $0.50 per share, or approximately 10%.
  • On March 16, 2026, Microvast reported a Q4 revenue miss and gross margin collapse tied to inventory impairment, followed by the 34.2% share decline.
  • The complaint contends these events corrected prior alleged impressions about profitability, capacity timing, and demand visibility.

Why the Market Impact Allegations Matter

The lawsuit asserts that each stock-price reaction reflected investors reassessing Microvast’s public statements against later company disclosures and market reports. For shareholders who purchased during the Class Period, the alleged harm centers on whether MVST traded at prices affected by statements concerning margins, production capacity, and customer demand.

“Corporate disclosures about margins, production timing, and customer demand can move markets when investors rely on those statements to value a company. Here, the complaint alleges that MVST investors suffered losses as later events called those prior representations into question.” — Joseph E. Levi, Esq.

Submit your information here or call (212) 363-7500.

Levi & Korsinsky, LLP is a nationally recognized shareholder rights firm. Over the past 20 years, the firm has secured hundreds of millions of dollars for aggrieved shareholders. Ranked in ISS Top 50 for seven consecutive years.

Frequently Asked Questions About the MVST Lawsuit

Q: How much did MVST stock drop? A: Shares fell approximately 34.2%, a decline of $0.79 per share, after Microvast disclosed Q4 2025 revenue of $96.5 million, gross margin of 1.0%, and a $32.5 million inventory impairment. Investors who purchased shares during the Class Period at allegedly inflated prices and suffered losses may be eligible to seek compensation.

Q: What specific misstatements does the MVST lawsuit allege? A: The complaint alleges Microvast made materially false or misleading statements regarding its ability to reach high gross margin targets, complete the Huzhou Phase 3.2 expansion by the end of 2025, and manage customer rollout and inventory risks during the Class Period.

Q: What court was the MVST class action filed in? A: The case was filed in the United States District Court for the Southern District of Texas, Houston Division, and is governed by the Private Securities Litigation Reform Act of 1995.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.

Q: What documents are useful for evaluating MVST trading losses? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices are generally useful for evaluating losses.

Q: What if I already sold my MVST shares, can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.

Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. If there is a settlement or recovery, eligible class members generally submit a claim form to seek their portion.

Attorney Advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo

PRIM Deadline Alert: Levi & Korsinsky Reminds Primoris Services Corporation (PRIM) Investors of Securities Class Action Deadline on September 21, 2026

PRIM Deadline Alert: Levi & Korsinsky Reminds Primoris Services Corporation (PRIM) Investors of Securities Class Action Deadline on September 21, 2026

Primoris timeline disclosure events are alleged to show how project-cost problems progressed from earlier warning signs to a June 2026 guidance reset tied to six renewable energy projects.

NEW YORK–(BUSINESS WIRE)–Levi & Korsinsky, LLP notifies investors in Primoris Services Corporation (NYSE: PRIM) that a class action has been filed on behalf of shareholders who purchased securities between August 5, 2025 and June 22, 2026. See if you could be eligible to recover or call (212) 363-7500.

PRIM fell $23.39 per share, or 21.6%, from $108.34 to $84.95 on June 23, 2026. The lead plaintiff deadline is September 21, 2026.

Primoris Timeline Disclosure Events Alleged in the Complaint

The securities action alleges that Primoris reassured investors about disciplined bidding, estimating processes, project execution, and risk management while significant fixed-price renewable energy projects were allegedly experiencing cost overruns, delays, and margin pressure.

The timeline begins with second-quarter 2025 results and continues through a sequence of 2026 disclosures. As claimed, the timeline shows how disclosures provided additional information about renewable energy project execution problems before the June 22, 2026 business update identified substantial challenges affecting six projects.

Timeline of Alleged Disclosure Failures

  • August 5, 2025: Primoris discussed second-quarter results and allegedly emphasized disciplined bidding, project execution, and risk management for its Energy segment.
  • February 23, 2026: Primoris disclosed increased costs on certain renewable energy projects, challenging soil conditions, and margin compression, followed by an approximately 8% decline to $151.92 on February 24, 2026.
  • May 5, 2026: Primoris reported revenue and margin pressure, delayed project starts, weaker first-quarter results, and a reduced full-year 2026 EPS outlook, followed by a decline to $101.23 on May 6, 2026.
  • June 8, 2026: Primoris announced the immediate departure of its President of Renewables, and Guggenheim Securities reportedly questioned whether the Company had fully scoped ongoing solar project challenges.
  • June 22, 2026: Primoris announced an internal review, supported by an independent third-party industry expert, identified substantial cost overruns, project delays, and execution challenges affecting six renewable energy projects.

Why the Chronology Matters for PRIM Shareholders

The complaint contends that Primoris’ financial guidance depended on reliable cost-to-complete forecasting because the Company used a cost-to-cost input method for long-term contracts. The action alleges that deficiencies in estimating and project oversight caused expected project costs to be understated and margin deterioration to be recognized later than it should have been.

“Timely disclosure of material developments is fundamental to fair and efficient markets. The alleged sequence here is important because investors were receiving updated guidance while the complaint claims project-cost issues were still not fully reflected.” — Joseph E. Levi, Esq.

By June 22, 2026, Primoris had reduced 2026 Adjusted EPS guidance to $2.05 to $2.60 and Adjusted EBITDA guidance to $275 million to $325 million. The lawsuit alleges that the guidance reset represented the culmination of earlier disclosure failures involving renewable energy project costs and execution.

Calculate your potential recovery or call (212) 363-7500.

ABOUT LEVI & KORSINSKY, LLP — Over the past 20 years, Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report.

Frequently Asked Questions About the PRIM Lawsuit

Q: What is the PRIM class action lawsuit about? A: A securities class action has been filed against Primoris Services Corporation (NYSE: PRIM) alleging materially false and misleading statements between August 5, 2025 and June 22, 2026. Shares fell approximately 21.6% after the Company announced an internal review identifying substantial cost overruns, project delays, and execution challenges affecting six renewable energy projects.

Q: How much did PRIM stock drop? A: Shares fell approximately 21.6%, a decline of $23.39 per share, from $108.34 to $84.95 on June 23, 2026 after Primoris announced the internal review findings, slashed 2026 guidance, and announced the resignation of its Chief Operating Officer.

Q: What specific misstatements does the PRIM lawsuit allege? A: The complaint alleges Primoris made materially false or misleading statements regarding disciplined bidding, estimating processes, project controls, cost-to-complete forecasting, and its ability to manage risk on fixed-price renewable energy projects.

Q: What court was the PRIM class action filed in? A: The case was filed in the United States District Court for the Northern District of Texas, Dallas Division, and is governed by the Private Securities Litigation Reform Act of 1995.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.

Q: What documents are useful for evaluating PRIM losses? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices are useful for evaluating potential losses.

Q: What if I already sold my PRIM shares, can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.

Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. If there is a settlement or recovery, eligible class members generally submit a claim form to seek their portion.

Q: What does it cost me to participate? A: There is no upfront cost for an initial evaluation. Securities class actions are generally handled on a pure contingency basis, and any attorneys’ fees and expenses awarded to class counsel are subject to court approval.

Attorney Advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo

REGN Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Regeneron Pharmaceuticals Securities Lawsuit – Contact Levi & Korsinsky

REGN Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Regeneron Pharmaceuticals Securities Lawsuit – Contact Levi & Korsinsky

Ryan Crowe Regeneron securities defendant liability allegations focus on investor-facing statements about the Phase III Fianlimab-Libtayo Study before REGN shares declined $102.09 per share from the Class Period high.

NEW YORK–(BUSINESS WIRE)–
Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) that a class action has been filed on behalf of shareholders who purchased securities between August 1, 2025 and May 15, 2026. Find out if you could qualify to recover your per-share losses. You may also contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.

REGN declined from a Class Period high of $731.77 on April 28, 2026 to $629.68 after the May 15, 2026 after-market announcement, a $102.09 per-share decline, or approximately 13.95%. The lead plaintiff deadline is September 14, 2026.

Ryan Crowe Regeneron Securities Defendant Liability Allegations

As named in the action, Ryan Crowe served as Regeneron’s Senior Vice President of Investor Relations and Strategic Analysis during the Class Period. The complaint identifies investor-facing presentations in which Crowe allegedly discussed the Phase III Fianlimab-Libtayo Study, prior Phase I results, expectations for progression-free survival, and the significance of slowing event accrual.

The action claims those communications contributed to an allegedly misleading impression that the study remained positioned to demonstrate meaningful clinical differentiation over existing standards of care. Plaintiffs allege that investors were not adequately informed that the prolonged event-rate slowdown reflected heightened risk to the trial’s statistical validity and primary endpoint.

Crowe’s Alleged Role in Investor Communications

  • Crowe is named as an individual defendant in the securities action.

  • The complaint identifies his role in discussing Regeneron’s oncology pipeline with investors and analysts.

  • His alleged statements referenced Phase I pooled results, including a 57% objective response rate and 24-month median progression-free survival.

  • Plaintiffs claim the public messaging understated the risk that the Phase III study would fail to show statistically significant PFS improvement.

  • The complaint alleges the later protocol expansion and failed primary endpoint corrected prior alleged misstatements.

Accountability Questions Raised by the Filing

The securities action asserts claims under Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5. As pleaded, Crowe’s investor-relations function is relevant because the challenged statements were allegedly directed to the market during a period when REGN shares traded at prices plaintiffs claim were artificially inflated.

“Individual officers who communicate with investors about clinical-trial progress should ensure those statements are accurate, complete, and appropriately qualified. Here, the action alleges that public commentary about PFS event accrual and clinical differentiation did not match the risks facing the Phase III study.” — Joseph E. Levi, Esq.

Submit your information here or call (212) 363-7500.

ABOUT LEVI & KORSINSKY, LLP — Over the past 20 years, Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report. Investors who suffered losses have until September 14, 2026 to seek appointment as lead plaintiff.

Frequently Asked Questions About the REGN Lawsuit

Q: What is the REGN class action lawsuit about? A: A securities class action has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) alleging materially false and misleading statements between August 1, 2025 and May 15, 2026. Shares fell approximately 13.95% from the Class Period high after the Company disclosed a protocol amendment and later announced that the Phase III Fianlimab-Libtayo Study did not reach statistical significance for its primary PFS endpoint.

Q: Who may be eligible in the REGN investor lawsuit? A: Investors who purchased REGN stock or securities between August 1, 2025 and May 15, 2026 and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses, not on whether you still hold the shares.

Q: What court was the REGN class action filed in? A: The case was filed in the United States District Court for the Southern District of New York and is governed by the Private Securities Litigation Reform Act of 1995.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.

Q: What documents are useful for evaluating REGN losses? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices are typically useful for evaluating potential losses.

Q: What if I already sold my REGN shares, can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.

Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. If there is a settlement or recovery, eligible class members generally submit a claim form to seek their portion.

Q: What does it cost me to participate? A: There is no upfront cost to contact the firm. Securities class actions are generally handled on a pure contingency basis. No upfront fees, no retainer, and no out-of-pocket costs. Any attorneys’ fees and expenses awarded to class counsel are subject to court approval.

Attorney Advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

[email protected]

Tel: (212) 363-7500

Fax: (212) 363-7171

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo

Levi & Korsinsky Reminds The Simply Good Foods Company Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 13, 2026 – SMPL

Levi & Korsinsky Reminds The Simply Good Foods Company Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 13, 2026 – SMPL

A securities class action alleges Simply Good Foods concealed a bloated organizational structure, ballooning general and administrative spending, and heavy discounting used to mask margin erosion, while SMPL shares lost more than 70% of their value.

NEW YORK–(BUSINESS WIRE)–
Levi & Korsinsky, LLP alerts investors in The Simply Good Foods Company (NASDAQ: SMPL) of a pending securities class action on behalf of shareholders who purchased securities between October 24, 2024 and April 8, 2026. Check if you might be eligible to recover your investment losses. You may also contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.

Ultimately, SMPL shares declined more than 27%, about $10.44 per share, following a two-day decline to close at $10.44 on April 10, 2026. The Court has set October 13, 2026 as the deadline to apply for lead plaintiff appointment.

“Investors deserve transparency about material risks that could affect their investments. The complaint alleges that Simply Good Foods described its OWYN integration in confident terms while an inefficient cost structure and above-historical discounting were allegedly eroding margins.” — Joseph E. Levi, Esq.

The Alleged Cost Structure and Discounting Concealment

The lawsuit asserts that while management publicly described the $280 million OWYN acquisition as delivering on model commitments, the Company had allegedly built a layered, bloated organizational structure and materially increased general and administrative spending to compensate for the loss of key managerial personnel. As alleged, the Company then turned to discounts and promotional activity above historical practices in an effort to prop up short-term sales, further compressing margins.

Margin Erosion in Nutritional Snacking

  • Target gross margins of approximately 40% were allegedly running in the middle 30s.

  • General and administrative dollars allegedly grew faster than the underlying business.

  • Marketing and brand support for OWYN was allegedly cut to stem margin erosion, further depressing sales.

  • Above-historical discounting allegedly failed to produce the intended sales turnaround.

  • Fiscal 2026 net sales guidance was ultimately slashed to a range of negative 7% to negative 10%.

  • A cumulative $200 million impairment was recorded against OWYN assets, more than 70% of the purchase price.

Why Cost Discipline Adequacy Allegedly Matters to Investors

The action claims that investors purchased SMPL securities at artificially inflated prices while these structural pressures were not disclosed. On April 9, 2026, the Company reported a $187 million OWYN impairment charge and OWYN quarterly sales contraction of nearly 17%.

Learn more about the case or call (212) 363-7500.

ABOUT LEVI & KORSINSKY, LLP — Over the past 20 years, Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report. Investors who suffered losses have until October 13, 2026 to seek appointment as lead plaintiff.

Frequently Asked Questions About the SMPL Lawsuit

Q: Who is notifying investors about the SMPL securities class action? A: Levi & Korsinsky, LLP is notifying investors that a securities class action has been filed on behalf of investors who purchased SMPL securities during the class period. The firm is nationally recognized, ranked in the ISS Top 50 for seven consecutive years, and has recovered hundreds of millions of dollars for aggrieved investors.

Q: Who is eligible to join the SMPL investor lawsuit? A: Investors who purchased SMPL stock or securities between October 24, 2024 and April 8, 2026 and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses — not on whether you still hold the shares.

Q: What specific misstatements does the SMPL lawsuit allege? A: The complaint alleges The Simply Good Foods Company made materially false or misleading statements regarding the integration and performance of the OWYN acquisition, its cost structure, and its discounting practices during the Class Period. When the Company disclosed a $187 million OWYN impairment charge, a nearly 17% contraction in OWYN quarterly sales, and slashed fiscal 2026 guidance, the stock price declined sharply.

Q: What do SMPL investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible as an absent class member.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.

Q: What if I already sold my SMPL shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.

Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in the securities class action, they are generally handled on a contingency basis, with any attorneys’ fees and expenses subject to court approval.

Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. If there is a settlement or recovery, eligible class members generally submit a claim form to seek their portion.

Attorney Advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLP\

Joseph E. Levi, Esq.\

Ed Korsinsky, Esq.\

33 Whitehall Street, 27th Floor\

New York, NY 10004\

[email protected]\

Tel: (212) 363-7500\

Fax: (212) 363-7171

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo

Levi & Korsinsky Reminds Aardvark Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 13, 2026 – AARD

Levi & Korsinsky Reminds Aardvark Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 13, 2026 – AARD

Pension funds, asset managers, and other fiduciaries holding Aardvark Therapeutics, Inc. (NASDAQ: AARD) positions acquired in or after the February 2025 IPO may wish to evaluate lead plaintiff options, as a securities class action alleges the Company misrepresented the safety and tolerability of ARD-101 before a Phase 3 trial pause and a full FDA clinical hold.

NEW YORK–(BUSINESS WIRE)–
Levi & Korsinsky, LLP notifies institutional investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between February 13, 2025 and May 14, 2026. Request an institutional investor loss assessment. You may also contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.

Shares sold at the $16.00 IPO price now trade near $4.57, a decline of approximately $11.43 per share, or 71.4%. Aardvark issued 5,888,000 shares for proceeds of $87,613,440. To be considered for lead plaintiff, investors must file by October 13, 2026.

Notice to Institutional Holders

The pleading asserts that offering documents and subsequent public statements described ARD-101 as approximately 99% gut-restricted, with limited systemic absorption and no serious adverse events. The complaint charges that these representations understated the candidate’s safety risk. On February 27, 2026, the Company announced a voluntary pause of the Phase 3 HERO trial citing reversible cardiac observations above target therapeutic doses; on May 14, 2026, it announced that the FDA had placed a full clinical hold on the ARD-101 IND covering all ongoing studies.

ERISA and Fiduciary Considerations

Funds, advisers, and trustees that acquired AARD shares in or traceable to the IPO may hold among the largest documented losses in the class. As averred in the action, Securities Act claims under Sections 11 and 15 do not require proof of intent, a distinction that can affect how fiduciaries assess a position’s claim value.

Fiduciary Obligations and Recovery Options

  • Institutional holders with the largest provable losses are typically best positioned for lead plaintiff appointment.

  • Serving as lead plaintiff provides direct oversight of counsel, litigation strategy, and settlement decisions.

  • Plan fiduciaries may have documentation obligations regarding the monitoring and pursuit of portfolio claims.

  • Absent class members retain the ability to participate in any recovery without seeking lead plaintiff status.

  • Loss assessments are provided at no cost and without obligation.

“Institutional investors play a critical role in securities class actions, and here the alleged gap between representations of a gut-restricted safety profile and the subsequent full FDA clinical hold on ARD-101 is precisely the kind of issue sophisticated holders are well positioned to evaluate,” — Joseph E. Levi, Esq.

Contact us to learn more about institutional recovery options or call (212) 363-7500.

INSTITUTIONAL INVESTOR REPRESENTATION — Levi & Korsinsky, LLP provides sophisticated counsel to institutional investors evaluating lead plaintiff opportunities. The firm has recovered hundreds of millions of dollars. Ranked among ISS Top 50 for seven consecutive years.

Frequently Asked Questions About the AARD Lawsuit

Q: Who is eligible to join the AARD investor lawsuit? A: Investors who purchased AARD stock or securities between February 13, 2025 and May 14, 2026 and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses — not on whether you still hold the shares.

Q: What court was the AARD class action filed in? A: The case was filed in the United States District Court for the Southern District of California, governed by the Private Securities Litigation Reform Act of 1995.

Q: Who are the defendants named in the AARD lawsuit? A: The complaint names Aardvark Therapeutics, Inc. and individual defendants including senior executives and directors who signed SEC filings, made public statements, or certified financial disclosures.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.

Q: What do AARD investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible as an absent class member.

Q: What if I already sold my AARD shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.

Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in the securities class action, they are generally handled on a contingency basis, with any attorneys’ fees and expenses subject to court approval.

Q: What if I live outside the United States? A: U.S. securities class actions generally cover purchases on U.S. exchanges regardless of the investor’s country of residence.

Attorney Advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

[email protected]

Tel: (212) 363-7500

Fax: (212) 363-7171

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal

MEDIA:

Logo
Logo